Analyst consensus rating
Phathom Pharmaceuticals Analyst Rating: Strong Buy
PHAT is rated Strong Buy by 10 analysts with a $21.50 target. As of 2026-08-24.
Direct answer
Phathom Pharmaceuticals's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.50.
Forecast evidence checked August 24, 2026.
Get free Phathom Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.87
- Average price target
- $21.50
- High price target
- $29.00
- Low price target
- $13.00
- Low target gap
- +46.6%
- Target upside
- +142.4%
- High target gap
- +226.9%
- Target range width
- 180.4%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Phathom Pharmaceuticals?
Phathom Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $21.50.
How far are Phathom Pharmaceuticals's low and high targets from the recorded price?
The low target implies +46.6%, while the high target implies +226.9%.
How many analysts are included in Phathom Pharmaceuticals's consensus?
The verified consensus includes 10 analysts.
How is Phathom Pharmaceuticals's target upside or downside calculated?
The average target of $21.50 is divided by the recorded price of $8.87, then one is subtracted to produce +142.4%. This does not guarantee a future return.
When was Phathom Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.